Despite considerable preclinical interest in targeting the mTOR pathway in glioma, clinical trials using mTOR inhibitors have demonstrated limited efficacy in slowing tumor progression [122,123,124,125]. This evidence concerns the gene MTOR and central nervous system cancer.